WVWilhelm A. J. W. Vos

Wilhelm A. J. W. Vos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wilhelm A. J. W. Vos has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Longitudinal plasma proteomic signatures of elite and viremic spontaneous HIV controllers

    by Nadira Vadaq, Albert L. Groenendijk, Jéssica C. dos Santos, Kavita Mehta, Ferdinand W.N.M. Wit, Wilhelm A. J. W. Vos, Martinus J. T. Blaauw, Louise E. van Eekeren, Laurens Lambrechts, Sofie Rutsaert, et al.

    A small percentage of people living with HIV (PLHIV) spontaneously regulate viral replication without suppressive antiretroviral treatment (ART) and are categorized into ‘elite controllers’ (EC, HIV-RNA < 50 c/mL) and ‘viremic controllers’ (VC, HIV-RNA between 50-10,000 c/ml). Some EC and VC may lose controller status in time. Here we provide extensive plasma proteomics to identify biomarkers and pathways related to spontaneous viral control and its long-term preservation among 36 EC and 147 VC (discovery) and 14 EC and 5 VC (validation). VC exhibited higher concentrations of CRTAM, LY9, and CD6 and lower concentrations of VAT1 compared to EC in both the discovery and validation cohort. Longitudinal analysis of pre- and post-ART samples (median follow-up: 5.3 years) revealed downregulation of various immune-related proteins in both EC and VC. Over a 17-year follow-up period, loss of viral control occurred in 31% of VC and 3% of EC. T-cell associated proteins (CRTAM, LY9, CD6), along with ICAM3, SH2D1A, C1QL2, and CNGB3, predicted loss of viral control years before its occurrence. Markers of chronic immune activation (sPD-L1, sCD25, IL-10, TGF-β, IFN-γ, and TNF-α) and systemic inflammation (TNF, IL-1β, IL-6, and sCD14) were not predictive. Our findings underscore the dynamic interplay between T cell function and viral replication in maintaining HIV control and identify key biomarkers that predict viral load surges.


  • Open Access

    Plasma proteomic signatures of liver steatosis and fibrosis in people living with HIV: a cross-sectional study

    by Louise E. van Eekeren, Quirijn de Mast, Elise M.G. Meeder, Adriana Navas, Albert L. Groenendijk, Marc J.T. Blaauw, Wilhelm A.J.W. Vos, Nadira Vadaq, Jéssica C. Dos Santos, Joost Rutten, et al.


  • Open Access

    Traditional Cardiovascular Risk Factors Are Stronger Related to Carotid Intima‐Media Thickness Than to Presence of Carotid Plaques in People Living With HIV

    by Marc J. T. Blaauw, Marvin A. H. Berrevoets, Wilhelm A. J. W. Vos, Albert L. Groenendijk, Louise E. van Eekeren, Nadira Vadaq, Gert Weijers, Andre J. A. M. van der Ven, Joost H. W. Rutten, Niels P. Riksen

    Background: Cardiovascular disease is a major cause of morbidity and mortality in people living with HIV, who are at higher risk than the general population. We assessed, in a large cohort of people living with HIV, which cardiovascular, HIV‐specific, and lipoproteomic markers were associated with carotid intima‐media thickness (cIMT) and carotid plaque presence. We also studied guideline adherence on lipid‐lowering medication in individuals with high and very high risk for cardiovascular disease. Methods and Results: In 1814 individuals with a median (interquartile range) age of 53 (44–60) years, we found a carotid plaque in 909 (50.1%) and a median (interquartile range) intima‐media thickness of 0.66 (0.57–0.76) mm. Ultrasonography was used for the assessment of cIMT and plaque presence. Univariable and multivariable regression models were used for associations with cIMT and presence of plaques. Age, Black race, body mass index, type 2 diabetes, and smoking (pack years) were all positively associated with higher cIMT. Levels of high‐density lipoprotein cholesterol, specifically medium and large high‐density lipoprotein subclasses, were negatively associated with higher cIMT. Only age and prior myocardial infarction were positively related to the presence of a carotid plaque. Lipid‐lowering treatment was prescribed in one‐third of people living with HIV, who are at high and very high risk for cardiovascular disease. Conclusions: Traditional cardiovascular risk factors were significantly associated with higher cIMT but not with carotid plaques, except for age. HIV‐specific factors were not associated with both ultrasound measurements. Future studies are needed to elucidate which factors contribute to plaque formation. Improvement of guideline adherence on prescription of lipid‐lowering treatment in high‐ and very high‐risk patients for cardiovascular disease is recommended. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03994835.


  • Toward a myeloablative regimen with clinical potential: II. Treosulfan induces specific skin graft tolerance across haploidentical MHC barriers

    by M van Pel, D W J G van Breugel, W Vos, R E Ploemacher, C J P Boog

    Treosulfan is a water-soluble structural analog of busulfan, acting as a prodrug of alkylating epoxide species. It does not induce severe hepatotoxicity or veno-occlusive disease at or above the maximum tolerated dose, lacks significant nonhematological toxicity and has a limited organ toxicity. It is mainly indicated for the treatment of patients with ovarian cancer. In the present study, we report that permanent donor-specific tolerance and stable mixed multilineage chimerism can successfully be achieved across haploidentical MHC barriers when Treosulfan is administered in combination with anti-T-cell mAb and T-cell-depleted donor bone marrow cells. Furthermore, we show that less T-cell suppression is required when Treosulfan is included in the conditioning regimen. In conclusion, Treosulfan is a well-tolerated myeloablative agent with a low toxicity, and is a promising candidate drug for conditioning prior to bone marrow transplantation.


  • All infiltrating T‐lymphocytes in Hodgkin's disease express immunohistochemically detectable T‐cell receptor ζ‐chains in situ

    by D F Dukers, J J Oudejans, E H Jaspars, M Gras, W Vos, J M Middeldorp, C J L M Meijer, E Bloemena

    Aim: We studied the expression of TCR ζ‐chain on tumour‐infiltrating lymphocytes in EBV‐positive and EBV‐negative cases of Hodgkin's disease (HD), to assess whether downregulation of TCR ζ‐chain on tumour‐infiltrating lymphocytes might be a mechanism for immune escape of the neoplastic cells.Methods and results: By immunohistochemistry we investigated tissue of 27 cases of primary HD, both paraffin embedded and frozen, for the presence of T‐cell receptor complex ζ‐chain and other T‐cell markers on the reactive cells. Strong membranous staining of TCR ζ‐chain was present in all cases in frozen tissue. In contrast, in paraffin‐embedded material substantial loss of TCR ζ‐chain was detected in old (> 6 years) tissues. However, no differences in either the number of positive cells or their staining intensity were observed in EBV‐positive and negative cases of HD as detected in frozen tissue. Storage of paraffin‐embedded tissue leads to a rapid and substantial loss of TCR ζ‐chain reactivity compared to frozen material of the same HD cases. Staining reactivity of other T‐cell markers (CD3, CD4 and CD8) on paraffin‐embedded material remained unaffected. Immunofluorescent double‐staining confirmed colocalization and coexpression of TCR ζ‐chain and CD3.Conclusions: In frozen biopsies of primary HD TCR ζ‐chain was expressed on all reactive CD3‐positive cells, both in EBV‐positive and EBV‐negative cases. This suggests that ζ‐chain downregulation is not a likely mechanism whereby neoplastic cells of HD can escape immune surveillance.